Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interferon-α Prevents Leukemia Relapse of AML Patients Undergoing HLA-identical Allogeneic Hematopoietic Stem Cell Transplantation With Pretransplant MRD

NCT03121079 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03121079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03121079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interferon-α Prevents Leukemia Relapse of AML Patients Undergoing HLA-identical Allogeneic Hematopoietic Stem Cell Transplantation With Pretransplant MRD
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Withdrawn
Start date
May 1, 2017
Completion date
December 31, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopietic stem cell transplantation, interferon-a-2b, prevention, relapse